Free Trial

DiaMedica Therapeutics (DMAC) Competitors

$2.85
+0.02 (+0.71%)
(As of 05/23/2024 ET)

DMAC vs. IMUX, CLRB, ADAG, ABEO, VTGN, FGEN, NVCT, CLSD, CRVO, and RZLT

Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Immunic (IMUX), Cellectar Biosciences (CLRB), Adagene (ADAG), Abeona Therapeutics (ABEO), Vistagen Therapeutics (VTGN), FibroGen (FGEN), Nuvectis Pharma (NVCT), Clearside Biomedical (CLSD), CervoMed (CRVO), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.

DiaMedica Therapeutics vs.

Immunic (NASDAQ:IMUX) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment.

51.8% of Immunic shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunic's return on equity of -36.21% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunicN/A -161.82% -118.57%
DiaMedica Therapeutics N/A -36.21%-34.45%

Immunic presently has a consensus price target of $8.50, indicating a potential upside of 585.48%. DiaMedica Therapeutics has a consensus price target of $7.00, indicating a potential upside of 145.61%. Given DiaMedica Therapeutics' higher possible upside, equities research analysts plainly believe Immunic is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunic
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
DiaMedica Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Immunic received 4 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. Likewise, 65.73% of users gave Immunic an outperform vote while only 62.07% of users gave DiaMedica Therapeutics an outperform vote.

CompanyUnderperformOutperform
ImmunicOutperform Votes
94
65.73%
Underperform Votes
49
34.27%
DiaMedica TherapeuticsOutperform Votes
90
62.07%
Underperform Votes
55
37.93%

Immunic has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunicN/AN/A-$93.61M-$1.83-0.68
DiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-5.09

In the previous week, Immunic had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Immunic and 0 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.22 beat Immunic's score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company Overall Sentiment
Immunic Neutral
DiaMedica Therapeutics Neutral

Summary

Immunic beats DiaMedica Therapeutics on 8 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAC vs. The Competition

MetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$107.25M$6.80B$5.08B$8.03B
Dividend YieldN/A2.73%2.81%3.93%
P/E Ratio-5.099.15118.3014.12
Price / SalesN/A258.452,560.6976.05
Price / CashN/A35.7135.9531.61
Price / Book2.345.935.424.57
Net Income-$19.38M$139.04M$104.41M$213.99M
7 Day Performance-10.09%-2.26%-1.76%-1.85%
1 Month Performance16.33%1.53%2.35%2.33%
1 Year Performance3.26%-6.44%3.19%6.84%

DiaMedica Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMUX
Immunic
2.0091 of 5 stars
$1.27
-1.6%
$8.50
+569.3%
-35.4%$114.40MN/A-0.6977Analyst Revision
News Coverage
CLRB
Cellectar Biosciences
1.5116 of 5 stars
$3.25
+2.8%
$20.00
+515.4%
+100.0%$116.51MN/A-1.0620
ADAG
Adagene
1.4448 of 5 stars
$2.59
-0.4%
$5.00
+93.1%
+89.2%$114.26M$18.11M0.00174Positive News
ABEO
Abeona Therapeutics
4.2806 of 5 stars
$4.31
-3.1%
$21.00
+387.2%
+32.0%$117.88M$3.50M-1.35N/A
VTGN
Vistagen Therapeutics
1.4279 of 5 stars
$4.38
-1.4%
$19.00
+333.8%
+3.8%$118.35M$1.11M0.0037
FGEN
FibroGen
3.8384 of 5 stars
$1.19
-0.8%
$17.00
+1,328.6%
-92.6%$118.37M$147.75M-0.49486Gap Down
NVCT
Nuvectis Pharma
2.2123 of 5 stars
$6.08
+1.7%
$21.00
+245.4%
-60.7%$111.63MN/A-4.3113Positive News
CLSD
Clearside Biomedical
2.4934 of 5 stars
$1.49
+12.0%
$4.50
+202.0%
+23.6%$111.35M$8.23M-2.7130High Trading Volume
CRVO
CervoMed
1.2133 of 5 stars
$19.44
-1.5%
$57.50
+195.8%
N/A$119.95M$7.14M0.008Positive News
RZLT
Rezolute
2.7733 of 5 stars
$3.00
+6.8%
$8.80
+193.3%
+49.3%$120.39MN/A-2.6357Analyst Forecast
High Trading Volume

Related Companies and Tools

This page (NASDAQ:DMAC) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners